NCT06752083View on ClinicalTrials.gov

Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

CompletedOBSERVATIONAL
Enrollment

219

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 15, 2024

Conditions
HPV Infection
Interventions
DIETARY_SUPPLEMENT

AHCC® (Active Hexose Correlated Compound)

3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.

BIOLOGICAL

Gardasil 9®

Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.

Trial Locations (1)

Unknown

University of Insubria, Varese

All Listed Sponsors
collaborator

Università degli Studi dell'Insubria

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER